Edwards Lifesciences Corporation


SKU: EW Category:


In the third quarter, Edwards Lifesciences witnessed decent global sales growth, achieving an 11% increase to $1.5 billion, driven by its diverse and innovative therapies. Within the Transcatheter Aortic Valve Replacement (TAVR) sector, Edwards Lifesciences experienced strong demand for their leading SAPIEN platform, with third-quarter sales totaling $961 million, marking a 10% year-over-year increase. Edwards Lifesciences is also pleased with the enrollment pace in their pivotal trial ALLIANCE, aimed at studying the groundbreaking SAPIEN X4, the next-generation TAVR technology. Edwards also experienced growth in Japan, reflecting market recovery and strong adoption of SAPIEN 3 Ultra RESILIA. Overall, the company is dedicated to enhancing the diagnosis and treatment of underserved patients worldwide, firmly believing in the potential for TAVR to become a $10 billion opportunity by 2028. In the field of Transcatheter Mitral and Tricuspid Therapies (TMTT), Edwards achieved several significant milestones, driven by the rapid adoption of the PASCAL PRECISION platform and the activation of additional centers in the U.S. and Europe, coupled with TEER procedure growth. They also collaborated with Mindray in the quarter. This milestone signifies the integration of Mindray’s BeneVision N-Series patient monitoring system with the Edwards FloTrac sensor for hemodynamic monitoring in the North American market.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!